Skip to main content
Premium Trial:

Request an Annual Quote

This Week in Cancer Research: Nov 4, 2011

Premium

The University of Pennsylvania's Lin Zhang and colleagues report in the online advance section of Cancer Research their new genetic screening approach to detect oncomirs. They used their combined array-based comparative genomic hybridization and functional library screening method to find mir-30d, which they say "regulates tumor cell proliferation, apoptosis, senescence, and migration."

And in the current issue, researchers led by Vanderbilt University's Carlos Arteaga performed a kinome-wide siRNA screen of ER+ breast cancer cells that are resistant to long-term estrogen deprivation to try to identify kinases those cells need to grow. From this, they found that the insulin receptor InsR is needed for growth, and that InsR and/or insulin-like growth factor-I receptor inhibition prevented growth. "We conclude that therapeutic targeting of both InsR and IGF-IR should be more effective than targeting IGF-IR alone in abrogating resistance to endocrine therapy in breast cancer," the authors write.

Finally in Cancer Research, Johns Hopkins researchers report that the oral antifungal drug itraconazole prevents angiogenesis and tumor growth in non-small cell lung cancer. "These data suggest that itraconazole has potent and selective inhibitory activity against multiple key aspects of tumor-associated angiogenesis in vitro and in vivo, and strongly support clinical translation of its use," the researchers say. They add that they have begun a randomized phase II study to compare standard therapy to standard therapy plus itraconazole in patients with non-small cell lung cancer.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more